emtricitabine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 23 Diseases   7 Trials   7 Trials   302 News 


123456»
  • ||||||||||  Journal:  Emerging integrase resistance in an international perinatal virtual clinic. (Pubmed Central) -  Jan 29, 2025   
    Although uncommon, INSTI resistance is emerging, mainly in highly treatment experienced CAWHIV from LMIC, highlighting the global need for access to boosted protease inhibitors and novel classes, including formulations for children less than 35?kg.
  • ||||||||||  Journal:  Antimicrobial agents in agricultural fertilizers produced from sewage sludge - A cause for concern? (Pubmed Central) -  Jan 12, 2025   
    Although uncommon, INSTI resistance is emerging, mainly in highly treatment experienced CAWHIV from LMIC, highlighting the global need for access to boosted protease inhibitors and novel classes, including formulations for children less than 35?kg. Several AAs were successfully removed during the sludge treatment process (sulfasalazine, sulfapyridine, isoniazid, isonicotinic acid, erythromycin, clarithromycin, erythromycin N-desmethyl, clarithromycin N-desmethyl, azithromycin N-desmethyl, emtricitabine, ANP) with reduction ranging from 34
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion:  Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) -  Jan 9, 2025   
    P4,  N=155, Completed, 
    Several AAs were successfully removed during the sludge treatment process (sulfasalazine, sulfapyridine, isoniazid, isonicotinic acid, erythromycin, clarithromycin, erythromycin N-desmethyl, clarithromycin N-desmethyl, azithromycin N-desmethyl, emtricitabine, ANP) with reduction ranging from 34 Active, not recruiting --> Completed
  • ||||||||||  Pifeltro (doravirine) / Merck (MSD)
    Trial completion date, Trial initiation date, Trial primary completion date, Head-to-Head:  ELDORADO: DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-na (clinicaltrials.gov) -  Oct 30, 2024   
    P3,  N=610, Not yet recruiting, 
    Leveraging the largest pooled analysis of global PrEP studies to date, we demonstrate that F/TDF is safe and highly effective, even with less than daily dosing, in diverse clinical settings, geographies, populations, and routes of HIV-1 exposure. Trial completion date: Apr 2027 --> Nov 2027 | Initiation date: Apr 2024 --> Nov 2024 | Trial primary completion date: Apr 2026 --> Nov 2026
  • ||||||||||  emtricitabine / Generic mfg.
    Journal:  Electromimetic molecularly imprinted Polymersensor for wastewater emtricitabine. (Pubmed Central) -  Oct 13, 2024   
    The combination of Fe3O4 nanoparticles, electrically conducting polymer, and the MIP technology produced a novel, simple, cost-effective, and high-performance voltammetric MIP sensor for an anti-HIV drug, FTC. The result of this study shows that the sensor holds a significant promise for future onsite monitoring of emtricitabine in wastewater, pharmaceutical, and biological samples without prior sample pretreatment.
  • ||||||||||  emtricitabine / Generic mfg., lamivudine / Generic mfg.
    Review, Journal:  Treatment Management Challenges in Na (Pubmed Central) -  Sep 29, 2024   
    Given the potential benefits of 3TC in ART combinations, the investigation of M184V remains of high interest to clinicians and researchers, especially in certain regions with limited resources, and especially for its unusual effects. This is a review of the literature on the challenges in treating both na
  • ||||||||||  Aptivus (tipranavir) / Boehringer Ingelheim, Edurant (rilpivirine) / J&J, Viracept (nelfinavir) / ViiV Healthcare, Roche
    Journal:  Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China. (Pubmed Central) -  Sep 26, 2024   
    Among PI, resistance to tipranavir (0.8%), nelfinavir (0.6%), fosamprenavir (0.2%) and lopinavir (0.1%) was most frequent...The overall prevalence of PDR in Guangzhou was moderate, with relatively severe NNRTI resistance. Therefore, it remains crucial to continue monitoring PDR among newly diagnosed HIV-infected individuals.
  • ||||||||||  emtricitabine / Generic mfg.
    Preclinical, Journal:  Endogenous retroviruses modulate the susceptibility of mice to Staphylococcus aureus-induced mastitis by activating cGAS-STING signaling. (Pubmed Central) -  Sep 23, 2024   
    and MPO activity...Interestingly, inhibition of cGAS-STING by Ru.521 and H151 respectively, significantly alleviated S. aureus-induced mammary injury and inflammatory responses, which was associated with the inhibition of NF-?B and NLRP3 signaling pathways. In conclusion, our study revealed that ERVs regulate the development of S. aureus-induced mastitis in mice through NF-?B- and NLRP3-mediated inflammatory responses via the activation of cGAS-STING pathway, suggesting that targeting ERVs-cGAS-STING axis may be a potential approach for the treatment of S. aureus-induced mastitis.
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare
    Trial completion, Trial completion date:  DOLCE: Dolutegravir-Lamivudine for na (clinicaltrials.gov) -  Aug 28, 2024   
    P4,  N=230, Completed, 
    The beneficial effects on the memory domain of increasing CNS penetration effectiveness score suggest that ARV neuropenetration may have a role in cognitive function. Recruiting --> Completed | Trial completion date: Nov 2024 --> May 2024
  • ||||||||||  Trial completion date, Trial primary completion date:  LINE-AD: Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD (clinicaltrials.gov) -  Aug 2, 2024   
    P1,  N=35, Recruiting, 
    These findings have the potential to contribute to future strategies for HIV control and treatment. Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
  • ||||||||||  CoAprovel (irbesartan hydrochlorothiazide) / Sanofi, Prezista (darunavir) / J&J
    Journal:  Comparing the adsorption of micropollutants on activated carbon from anaerobically stored, organics-depleted, and nitrified urine. (Pubmed Central) -  May 27, 2024   
    In addition, we showed that the relative pharmaceutical removal in all solutions was independent of the initial pharmaceutical concentration unless the background organics matrix changed considerably. We conclude that removal of micropollutants in GAC columns from organics-depleted urine can be performed without clogging, but with the drawback of a higher carbon usage compared to removal from nitrified urine.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
    Emerging Integrase Resistance in the Perinatal Virtual Clinic: The Need for Protease Inhibitors (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_1329;    
    A second suppressed on nevirapine/3TC/ABC for 11 years simplified to DTG/3TC/ABC but failed 4 years later with an R263RK (intermediate DTG-R)...INSTI resistance is emerging in CALWHIV, most commonly in highly treatment experienced individuals from L/MIC. This highlights the global need for access to DRV/r, TXF and novel classes, including formulations for children <35kg.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    DTG Versus EFV Initiation in Pregnancy Is Not Associated With Postpartum Blood Pressure () -  Mar 16, 2024 - Abstract #CROI2024CROI_1265;    
    P3
    Background: Several studies in non-pregnant adults have suggested increases in blood pressure (BP) associated with dolutegravir (DTG) use, however findings are mixed...At sites in Uganda and South Africa, PLH initiating ART ?28w gestation were randomly assigned tenofovir+lamivudine/emtricitabine and either DTG or Efavirenz (EFV) as first-line therapy...These reassuring RCT data suggest that after adjustment for important pre-treatment covariates there was no association between DTG vs EFV initiated late in pregnancy and BP through 18 months postpartum. There is ongoing need for attention to the long-term cardiometabolic effects of DTG use in PLH.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    ART Adherence And Elevated Viral Load in Pregnant & Postpartum Women Initiating DTG Versus EFV (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_778;    
    P3
    EA was higher in DTG at visits with VL<20. Taken together, these data suggest that DTG may be associated with better ART adherence compared to EFV but is not more forgiving of the short-term non-adherence that occurs commonly during the postpartum period.
  • ||||||||||  emtricitabine / Generic mfg.
    A Rapid Emtricitabine Urine Lateral Flow Assay for Monitoring Daily Adherence to ART and PrEP (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_637;    
    We describe a lateral flow assay specific for FTC that is designed to detect whether a dose was taken within the past day. This daily adherence urine test has high sensitivity and specificity and can enhance point-of-care adherence monitoring for both ART and PrEP.
  • ||||||||||  vancomycin / Generic mfg., emtricitabine / Generic mfg.
    Analytical validation of aptamer-based blood drug measurements against clinical benchmark methods (Hybrid; Room 354 (Ernest N. Morial Convention Center)) -  Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_8225;    
    Our results demonstrate that aptamer-based sensors are selective for the free form of these drugs, and can achieve up to 95% positive correlation and 100% negative correlation with the benchmark assays. Given these results, aptamer sensors offer a promising path for point-of-care drug monitoring that is instantaneous and overcomes current barriers for broad implementation of drug monitoring in clinical settings.
  • ||||||||||  bictegravir (GS-9883) / Gilead
    Bictegravir as Universal Initial Antiretroviral Therapy: A National Target Trial Emulation Study (Poster hall) -  Mar 5, 2024 - Abstract #CROI2024CROI_482;    
    Given these results, aptamer sensors offer a promising path for point-of-care drug monitoring that is instantaneous and overcomes current barriers for broad implementation of drug monitoring in clinical settings. Background: Bictegravir (BIC) has been shown to be non-inferior to dolutegravir (DTG) as initial antiretroviral therapy (ART) in non-inferiority randomized controlled trials (RCTs)...However, BIC has not been compared to efavirenz (EFV) or raltegravir (RAL) (commonly prescribed in Mexico) and no superiority trials have been performed.We used data from the national antiretroviral surveillance system in Mexico to perform three target trial (TT) emulations for initial ART among PWH starting ART from 2019 onwards: BIC vs DTG, BIC vs EFV, and BIC vs RAL...People with missing viral load (VL), VL <500 copies/mm3, and/or missing CD4 count within the last year before ART start, those started on double-dose DTG and/or reduced-dose emtricitabine, lamivudine or tenofovir disoproxil fumarate were excluded...BIC is superior to RAL and EFV, but not DTG, as initial ART in treatment na
  • ||||||||||  Journal:  Analysis of ART effects and drug resistance in adult HIV/AIDS patients in Meigu County, Liangshan Prefecture, China. (Pubmed Central) -  Feb 6, 2024   
    Compared with the previous low ART efficacy in the county, this study showed that the overall virological failure (VF) resistance rate in the county is still low, dominated by resistance to EFV, NVP, 3TC, FTC, and didanosine (DDI). Due to economic constraints, the core regimen is still 3TC?+?TDF, but before initiating ART, testing for HIV-1 subtypes and resistance should be conducted to avoid resistance that can lead to VF, especially for patients with high risk factors for resistance as shown by epidemiologic investigations.
  • ||||||||||  emtricitabine / Generic mfg.
    Journal:  Use of genotypic HIV DNA testing: a DELPHI-type consensus. (Pubmed Central) -  Jan 25, 2024   
    Due to economic constraints, the core regimen is still 3TC?+?TDF, but before initiating ART, testing for HIV-1 subtypes and resistance should be conducted to avoid resistance that can lead to VF, especially for patients with high risk factors for resistance as shown by epidemiologic investigations. This DELPHI-type consensus will facilitate the strengthening and harmonization of good practice when performing HIV DNA sequencing.
  • ||||||||||  emtricitabine / Generic mfg.
    Review, Journal:  Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions. (Pubmed Central) -  Dec 4, 2023   
    Over the past decade, clinical trials have established the safety and tolerability of newer PEP regimens, particularly those containing integrase strand transfer inhibitors (INSTIs) combined with a tenofovir and lamivudine or emtricitabine backbone...Despite the increase in well tolerated options, PEP seems to be underused globally and links to other prevention services are suboptimal. Interventions to increase provider and community awareness of PEP are needed.
  • ||||||||||  emtricitabine / Generic mfg.
    Review, Journal, Adherence:  Adherence to Oral Pre-Exposure Prophylaxis Intervention by Transgender Women: A Systematic Review. (Pubmed Central) -  Nov 3, 2023   
    Participation and adherence to the intervention were low for TW compared to cisgender men who have sex with men (cMSM), and it was measured mostly by self-report (72.7%) or tenofovir-diphosphate/emtricitabine triphosphate dried blood spot (45.5%)...One limitation is that our sample size was dominated by two Thai studies with TW sex workers. Future studies should evaluate adherence to new PrEP modalities.
  • ||||||||||  Preclinical, Journal:  Carbonic anhydrase inhibition by antiviral drugs in vitro and in silico. (Pubmed Central) -  Oct 9, 2023   
    Future studies should evaluate adherence to new PrEP modalities. Herein, the selected five active antiviral drugs, abacavir, emtricitabine, lamivudine, ribavirin, and ritonavir, were assayed as inhibitors of two human isoforms of the metalloenzyme carbonic anhydrase (hCA, EC 4.2.1.1) involved in various physiological/pathological conditions...The hCA I, an isoform involved in some pathological conditions such as retinal or cerebral edema, was moderately inhibited by these five drugs at micromolar concentrations with K s spanning from 0.49?
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-na (ePosters) -  Oct 8, 2023 - Abstract #EACS2023EACS_490;    
    Low CD4+ count and inadequate HIV-1 suppression resulted in prolonged viral shedding of SARS-CoV-2, requiring antiviral combination therapy for clearance. Purpose :